0001493152-18-008194.txt : 20180605 0001493152-18-008194.hdr.sgml : 20180605 20180604191138 ACCESSION NUMBER: 0001493152-18-008194 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180604 ITEM INFORMATION: Other Events FILED AS OF DATE: 20180605 DATE AS OF CHANGE: 20180604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intiva BioPharma Inc. CENTRAL INDEX KEY: 0001625288 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262049376 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55320 FILM NUMBER: 18879669 BUSINESS ADDRESS: STREET 1: 4340 E KENTUCKY AVE STREET 2: SUITE 206 CITY: GLENDALE STATE: CO ZIP: 80246 BUSINESS PHONE: 3034957583 MAIL ADDRESS: STREET 1: 4340 E KENTUCKY AVE STREET 2: SUITE 206 CITY: GLENDALE STATE: CO ZIP: 80246 FORMER COMPANY: FORMER CONFORMED NAME: Kinder Holding Corp. DATE OF NAME CHANGE: 20141114 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): June 4, 2018

Intiva BioPharma Inc.
(Exact Name Of Registrant As Specified In Its Charter)

Commission File No.: 0-55320

Delaware		26-2049376
(State of Incorporation)		(I.R.S. Employer Identification No.)

4340 E Kentucky Ave, Suite 206, Glendale, CO		80246
(Address of Principal Executive Offices)		(ZIP Code)

Registrant’s Telephone Number, including area code: (973) 370-3768

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 8.01 Other Events.

On June 4, 2018, the registrant extended the expiration date of its Class B Warrants, currently June 7, 2018, to June 29, 2018, and also extended the expiration date of its Class C Warrants, currently July 14, 2018, to July 27, 2018.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/: Richard Greenberg

Richard Greenberg, Executive Vice President

June 4, 2018